Lei Zheng

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Exome capture sequencing of adenoma reveals genetic alterations in multiple cellular pathways at the early stage of colorectal tumorigenesis
    Donger Zhou
    The Key Laboratory of Cancer Prevention and Intervention of China National Ministry of Education, the Key Laboratory of Molecular Biology in Medical Sciences of Zhejiang Province, Cancer Institute, Hangzhou, Zhejiang, China
    PLoS ONE 8:e53310. 2013
  2. pmc Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma
    Lei Zheng
    The Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Gastroenterology 144:1230-40. 2013
  3. pmc Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer
    Lei Zheng
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    PLoS ONE 6:e19390. 2011
  4. pmc The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy
    Katherine M Bever
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    HPB (Oxford) 17:292-8. 2015
  5. pmc Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer
    Dung T Le
    The Sidney Kimmel Cancer Center, the Skip Viragh Center for Pancreatic Cancer, Research and Clinical Care, and the Sol Goldman Pancreatic Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Immunother 36:382-9. 2013
  6. pmc Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer
    Joseph M Herman
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Int J Radiat Oncol Biol Phys 86:678-85. 2013
  7. pmc Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer
    Kelly Foley
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA Graduate Program in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Sci Signal 8:ra77. 2015
  8. pmc TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner
    Kevin C Soares
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Oncotarget 6:43005-15. 2015
  9. pmc The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience
    Shalini Moningi
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Ann Surg Oncol 22:2352-8. 2015
  10. pmc Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer
    Darshil T Jhaveri
    Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland The Skip Viragh Center for Pancreatic Cancer Research and Clinical Care and The Sol Goldman Pancreatic Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
    Cancer Immunol Res 4:225-33. 2016

Collaborators

Detail Information

Publications26

  1. pmc Exome capture sequencing of adenoma reveals genetic alterations in multiple cellular pathways at the early stage of colorectal tumorigenesis
    Donger Zhou
    The Key Laboratory of Cancer Prevention and Intervention of China National Ministry of Education, the Key Laboratory of Molecular Biology in Medical Sciences of Zhejiang Province, Cancer Institute, Hangzhou, Zhejiang, China
    PLoS ONE 8:e53310. 2013
    ..Thus, the comparison of genomic mutations between adenoma and adenocarcinoma provides us a new insight into the molecular events governing the early step of colorectal tumorigenesis...
  2. pmc Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma
    Lei Zheng
    The Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Gastroenterology 144:1230-40. 2013
    ..Unlike single therapeutic agent studies that block immunosuppressive mechanisms, studies of combination therapies that include therapeutic vaccines have provided promising results...
  3. pmc Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer
    Lei Zheng
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    PLoS ONE 6:e19390. 2011
    ..Thus, ANXA2 is part of a novel molecular pathway underlying PDA metastases and a new target for development of PDA therapeutics...
  4. pmc The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy
    Katherine M Bever
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    HPB (Oxford) 17:292-8. 2015
    ..However, how stromal components should be assessed and how the characteristics of the stromal compartment determine clinical outcomes in PDA patients remain unknown...
  5. pmc Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer
    Dung T Le
    The Sidney Kimmel Cancer Center, the Skip Viragh Center for Pancreatic Cancer, Research and Clinical Care, and the Sol Goldman Pancreatic Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Immunother 36:382-9. 2013
    ..014) and enhancement of the T-cell repertoire (P = 0.031). In conclusion, checkpoint blockade in combination with GVAX has the potential for clinical benefit and should be evaluated in a larger study...
  6. pmc Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer
    Joseph M Herman
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Int J Radiat Oncol Biol Phys 86:678-85. 2013
    ..Gemcitabine-erlotinib therapy has demonstrated a survival benefit for patients with metastatic PDAC. Here we report the first phase 2 study of erlotinib in combination with adjuvant chemoradiation and chemotherapy for resected PDAC...
  7. pmc Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer
    Kelly Foley
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA Graduate Program in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Sci Signal 8:ra77. 2015
    ..Thus, AnxA2 and Sema3D may be new therapeutic targets and prognostic markers of metastatic PDA. ..
  8. pmc TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner
    Kevin C Soares
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Oncotarget 6:43005-15. 2015
    ..Therefore, our PDA preclinical model demonstrates a survival advantage in mice treated with an anti-TGF-β antibody combined with GVAX therapy and provides strong rational for testing this combinational therapy in clinical trials. ..
  9. pmc The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience
    Shalini Moningi
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Ann Surg Oncol 22:2352-8. 2015
    ..This study reviews our institutional experience of SBRT in the treatment of locally advanced (LAPC) and borderline resectable (BRPC) PCA...
  10. pmc Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer
    Darshil T Jhaveri
    Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland The Skip Viragh Center for Pancreatic Cancer Research and Clinical Care and The Sol Goldman Pancreatic Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
    Cancer Immunol Res 4:225-33. 2016
    ..These targets need further validation to be considered as possible pancreatic cancer biomarkers. Cancer Immunol Res; 4(3); 225-33. ©2016 AACR. ..
  11. pmc Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer
    Farzana Faisal
    Departments of Oncology, Surgery, and Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD Department of Surgery, University of Colorado School of Medicine, Denver, CO
    Am J Clin Oncol 39:18-26. 2016
    ..The standard treatment for locally advanced pancreatic cancer (LAPC) is not defined. The current study was conducted to assess the roles of chemotherapy and chemoradiation for LAPC treatment...
  12. pmc PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors
    Kevin C Soares
    Departments of Oncology Pathology Surgery The Sidney Kimmel Cancer Center The Skip Viragh Center for Pancreatic Cancer Research and Clinical Care The Sol Goldman Pancreatic Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD Amplimmune Inc, Gaithersburg, MD Department of Surgery, University of Colorado School of Medicine, Aurora, CO
    J Immunother 38:1-11. 2015
    ..Collectively, our study supports combining PD-1 or PD-L1 antibody therapy with a T cell inducing agent for PDA treatment. ..
  13. pmc Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns
    Tamna Wangjam
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Oncotarget 6:36903-10. 2015
    ..Further studies are needed to investigate how different diagnostic and treatment modalities affect the survival of this unique subpopulation of pancreatic cancer patients. ..
  14. pmc What is the Significance of Indeterminate Pulmonary Nodules in Patients Undergoing Resection for Pancreatic Adenocarcinoma?
    Katherine E Poruk
    Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Halsted 608, 600 N Wolfe Street, Baltimore, MD, 21287, USA
    J Gastrointest Surg 19:841-7. 2015
    ..The significance of indeterminate pulmonary nodules (IPNs) in patients undergoing resection of pancreatic ductal adenocarcinoma (PDAC) is unknown. We sought to define the prevalence and impact of IPN in such patients...
  15. pmc Impact of the time interval between MDCT imaging and surgery on the accuracy of identifying metastatic disease in patients with pancreatic cancer
    Siva P Raman
    1 Department of Radiology, Johns Hopkins University School of Medicine, JHOC 3251, 601 N Caroline St, Baltimore, MD 21287
    AJR Am J Roentgenol 204:W37-42. 2015
    ..This study examines the relationship between the interval between imaging and surgery and the accuracy of MDCT in determining the presence or absence of metastatic disease at surgery in patients with pancreatic cancer...
  16. pmc A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer
    Lei Zheng
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Ann Surg Oncol 21:3931-7. 2014
    ..Preclinical studies have supported the antitumor activity of immunization with a granulocyte-macrophage colony-stimulating factor (GM-CSF) producing murine colon tumor cell vaccine...
  17. pmc Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine
    Aaron J Schueneman
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Ann Surg Oncol 20:S725-30. 2013
    ..Although immune-based therapies are under rapid development, it is not known whether baseline complete blood counts, particularly lymphocytes, are associated with the clinical outcomes of patients receiving immunotherapies...
  18. pmc Effects of genomic changes in hepatitis B virus on postoperative recurrence and survival in patients with hepatocellular carcinoma
    Priya Mathews
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Ann Surg Oncol 20:1216-22. 2013
    ..To determine whether the genomic changes in hepatitis B virus (HBV) affect the clinical outcomes of hepatocellular carcinoma (HCC) in patients with HBV-associated HCC treated with curative surgical resection...
  19. pmc Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma
    Joseph M Herman
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
    Cancer 121:1128-37. 2015
    ....
  20. pmc The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma
    Aaron T Wild
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
    Am J Clin Oncol 38:259-65. 2015
    ..This study was conducted to determine if patients with locally advanced pancreatic cancer (LAPC) treated with definitive chemoradiation develop significant lymphopenia and if this affects clinical outcomes...
  21. pmc Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation
    Eric R Lutz
    Authors Affiliations Departments of Oncology, The Sidney Kimmel Cancer Center The Skip Viragh Center for Pancreatic Cancer Research and Clinical Care The Sol Goldman Pancreatic Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland and
    Cancer Immunol Res 2:616-31. 2014
    ....
  22. doi request reprint Multidisciplinary management of pancreatic cancer
    Rachit Kumar
    Department of Radiation Oncology and Molecular Radiation Sciences, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Surg Oncol Clin N Am 22:265-87. 2013
    ..In this review, the importance of multidisciplinary management of pancreatic cancer based on disease stage is discussed...
  23. pmc Young patients undergoing resection of pancreatic cancer fare better than their older counterparts
    Jin He
    Department of Surgery, Johns Hopkins University School of Medicine, 600 N Wolfe St, Osler 624, Baltimore, MD 21287, USA
    J Gastrointest Surg 17:339-44. 2013
    ..We investigated features of PDAC occurring in young patients (≤45 years) who underwent surgical resection in order to determine if any difference exists in comparison to elderly patients (≥70 years)...
  24. pmc Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer
    Darshil T Jhaveri
    Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD Department of Oncology, the Sidney Kimmel Comprehensive Cancer Center and the Skip Viragh Pancreatic Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
    Semin Oncol 41:559-75. 2014
    ..A combinatorial approach simultaneously targeting antigens on the PDA cell, stroma, and immunosuppressive cells should be employed. ..
  25. pmc A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma
    Ana De Jesus-Acosta
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB I, Room 590, Baltimore, MD 21231, USA
    Cancer Chemother Pharmacol 69:415-24. 2012
    ..We were interested in determining the clinical benefit of another three-drug regimen of gemcitabine, docetaxel and capecitabine (GTX) in patients with advanced pancreatic adenocarcinoma...